News

It was announced by Arcutis Biotherapeutics that the US Food and Drug Administration had accepted for review their NDA for roflumilast foam 0.3%.

A new study leveraging data from 184 countries based on 11 dietary factors provides an overview of the diet attributable burden of type 2 diabetes in the world today.

There are many reasons why biosimilars are not utilized in gastroenterology, mainly patients present younger and treatments can lose efficacy over time.

A single-center study from India sheds light on the safety and efficacy of biosimilar tenecteplase relative to the reference agent for patients with acute ischemic stroke.

New study data re-evaluating current guidelines for T1a melanoma excisions indicate that 5-mm margins may be adequate in order to maintain lower risk levels for melanoma recurrence.

Despite the recent advancements in the treatment of polymyalgia rheumatica, a need for more research focused on finding non-steroidal treatment options remains.

The proportion of premature infants diagnosed with ROP increased from 4.4% in 2003 to 8.1% in 2019, particularly among underserved populations.

Investigators address 2 questions: How can we better understand the biology of these rare disorders? How can we stimulate research and optimize the regulatory process to improve diagnosis and targeted treatment?

Although women with gout reported more severe symptoms and significantly worse illness perception and quality of life, they were given less information on ways to self-manage their condition.

A retrospective analysis of more than 3 million patients who received the mRNA COVID-19 vaccine found no association between vaccination and newly diagnosed RVO.

A new report tracks how the epidemic periods of RSV shifted throughout recent years, addressing the disruption in consistency during the 2020-2021 season.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

New data suggest 10 years of consecutive poverty is a greater risk factor for death than dementia, obesity and stroke among Americans.

Announced on April 14, the clearance allows for FreeStyle Libre 3 users to obtain real-time glucose readings on a large, easy-to-see screen directly from their back of arm sensors.

In this interview segment, Fleischer further described some of the key points about the peanut immunotherapy patch, DBV712, and the product’s phase 3 VITESSE trial.

Some traditional sarcopenia assessment techniques included direct measurements on cross sectional imaging, but cross sectional imaging also comes with increased time, cost, and radiation exposure.

Evidence shows digital cognitive behavioral therapy for insomnia is more effective than medication therapy, with comparable effectiveness to combination therapy.

In his interview, Fleischer discussed the beginning of a new phase 3 trial for a peanut immunotherapy patch known as DBV712.

State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.

Results revealed 92.45% of patients with fibromyalgia were simultaneously diagnosed with at least 1 type of psychiatric disorder, although most were diagnosed with 2 or more.

An analysis of data from patients presented to a pair of clinics in Greece over a 5-year period provides insight into potential differences in disease course, management, and presentation of psoriatic arthritis based on age at diagnosis.

New CDC data show high-impact chronic pain has been decreasing since 2016, though the issue continues to disparately impact certain populations.

The rate of CDI recurrence through week 9 using the efficacy analysis 3 definition was 13.8% for the high-dose VE303 group, compared to 37% for the low-dose VE303 group and 45.5% for the placebo group.

Results from the SELECT-PsA trials indicate patients with active PsA and axial involvement demonstrated greater clinical improvement with upadacitinib 15 mg versus placebo.

New research into allergic disease examined changes over time as well as the characterization of remission versus continued disease.

Phase 3 data show non-inferior efficacy of infliximab biosimilar CMAB008, which was well-tolerated with similar safety to its reference product.

No significant changes in the rate of flares during the 6-month period pre- or post-vaccination were observed in patients with either rheumatoid arthritis or psoriatic arthritis.

According to Horizon Therapeutics, the updated indication language reinforces the importance of access for patients across the full spectrum of TED activity or duration.

The study suggests long-term exposure to particulate matter PM2.5, nitrogen dioxide, and nitrogen oxide, may increase the risk of dementia.

No significant differences in the risk of myocardial infarction and other cardiovascular events were observed between patients with gout who received colchicine and those who did not.